Affitope PD01

Drug Profile

Affitope PD01

Alternative Names: Affitope-PD01A; Parkinson's disease vaccine - AFFiRiS; PD-01A; PD01

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AFFiRiS
  • Class Antiparkinsonians; Peptide vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 28 Aug 2018 No recent reports of development identified for phase-I development in Multiple system atrophy(Early-stage disease) in France (SC, Injection)
  • 28 Aug 2018 No recent reports of development identified for phase-I development in Parkinson's-disease(Early-stage disease) in Austria (SC, Injection)
  • 18 Apr 2017 AFFiRiS completes a phase I trial in Multiple system atrophy (Early-stage disease) in France (SC) (NCT02270489)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top